ENDRA Life Sciences (NDRA) Common Equity (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Common Equity for 11 consecutive years, with $6.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 328.31% year-over-year to $6.3 million in Q2 2026; TTM through Jun 2026 was $6.3 million, a 328.31% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, down 11.73% from the prior year.
• Common Equity was $6.3 million for Q2 2026 at ENDRA Life Sciences, up from $1.8 million in the prior quarter.
• Over five years, Common Equity peaked at $13.3 million in Q2 2022 and troughed at $171380.0 in Q3 2025.
• A 5-year average of $5.4 million and a median of $5.4 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 97.41% in 2025 and soared 328.31% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $7.2 million in 2022, then fell by 21.45% to $5.7 million in 2023, then plunged by 54.76% to $2.6 million in 2024, then fell by 11.73% to $2.3 million in 2025, then jumped by 179.18% to $6.3 million in 2026.
• The last three Common Equity figures came in at $6.3 million (Q2 2026), $1.8 million (Q1 2026), and $2.3 million (Q4 2025), per Business Quant data.